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Marginal zone B cell
Activation-induced cytidin-deaminase
B-lymphocyte activating factor
ChemokineThe frequent association of Sjögren's syndrome (SS) with non-Hodgkin's B cell lymphoma (NHL) provides an
exampleof the interplayof systemic autoimmunityand lymphoproliferativediseases, andanopportunity to study
the pathogenetic steps of lymphomagenesis. NHL develops in approximately 5% of SS patients. Parotidomegaly,
lymphadenopathy, inﬂammatory neuropathy and vasculitis have been found to be predictive of the development
of lymphoma. A subsequent NHL is also heralded by the appearance of cryoglobulinaemia and serum or urinary
monoclonal proteins. The typical histological type of NHL in SS is a low-grade extranodal marginal zone B cell
lymphoma. The authors discuss the proposed key immunopathologic steps of lymphomagenesis in SS in detail.
Recent results indicating the pathogenetic role of ectopic germinal centre formation in the involved exocrine
glands, the potential importance of an antigen-driven clonal proliferation of autoreactive B-lymphocytes, the
proposed roleof theB-lymphocyte activating factor (BAFF) andof further cytokines and,ﬁnally, the changesof the
chemokine milieu at the site of lymphoma development are highlighted.
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Take-home mes ages1. Introduction
The only malignancy, having a proven association with Sjögren's
syndrome (SS) is non-Hodgkin's lymphoma (NHL) [1]. Nevertheless,
this link between SS and NHL is one of the strongest among all the
known associations between systemic autoimmune diseases and
malignancies. The occurrence of NHL has been reported to be as
much as 44-fold greater than in the general population [2]. Subsequent
surveys also conﬁrmed a clearly increased risk of lymphomagenesis in
SS, although with somewhat lower standardized incidence ratios
ranging from 8.7 to 33.3 [3,4] and of 6.6 in themost recently published
series [5].ed. Tel./fax: +36 62 561 332.
ács).
l rights reserved.2. Clinical presentation of NHL in SS
TheprevalenceofNHLwas found tobe4.3% inSS in a largemulticentre
European study [6]. Other studies revealed similar occurrence rates [7,8].
Lymphoma development is typically a late event during the course of SS
with reported median SS disease durations ranging from 7.5 to 14 years
before the diagnosis of lymphoma [6,8,9]. A number of clinical factors
have been identiﬁed which occur more frequently in SS patients, who
subsequently develop NHL than in SS patients in general. These include
lymphadenopathy [6,8], parotid gland enlargement [2,6,8], inﬂammatory
neuropathy [6], and vasculitis [6,8] (including purpura) [5]. Laboratory
ﬁndingswhichappear tobepredictiveof lymphomadevelopmentare low
serum complement-4 (C4) levels [5,6,10], mixed monoclonal cryoglobu-
linaemia (type II cryoglobulinaemia) [6,11]; the latter being usually
associated with the presence of monoclonal immunoglobulin in the
serum [11], or free light chain in the urine [8]. Although, all of the above-
mentioned signs can be found in SS patients with no evidence of
204 L. Kovács et al. / Autoimmunity Reviews 9 (2010) 203–206lymphoma, patients with these features need thorough follow-up with
respect to the presence or the subsequent development of NHL.
3. Pathology
In the majority of patients, the histopathologic type of lymphoma
is mucosa-associated lymphoid tissue (MALT) type B cell lymphoma,
i.e. extranodal marginal zone B cell lymphoma. In about 30% of SS
patients, other types of NHL can be observed, in particular, diffuse
large B cell lymphoma (DLBCL), follicle centre lymphoma and
lymphoplasmocytoid cell lymphoma [5–7]. Overall, the MALT lym-
phoma cases typically present with a low-grade histological morphol-
ogy and a relatively benign clinical course, while about one-third of
the patients develop an intermediate- or high-grade lymphoma,
including DLBCL [6,11]. The origin of NHL is extranodal in approxi-
mately 80–85% of the patients, with the parotid gland being the most
frequent site [6,9]. Other mucosal sites including the stomach, lung,
genital mucosa or pharynx are also common.
In the MALT lymphoma subtype, the proliferating cells are CD20+/
IgD-/Bcl-2+ B-lymphocytes, with monocyte-like morphology and high
mitotic activity, pale nuclei and evident nucleoli, consistent with the
marginal zone B cell appearance [9,12]. In the salivary glands, these cells
diffusely inﬁltrate the parenchyma, forming dense sheets of proliferat-
ing cells, often destroying and subverting the glandular structure. In
extranodal sites, the lymphomatous expansion of B cells always arises in
the proximity of ectopic germinal centre-like structures, a peculiar
phenomenon reported to evolve in approximately 20–30% of the SS
patients [12,13].
4. The cellular basis of lymphomagenesis—from benign
lymphoproliferation to malignancy
In SS, the predominant cellular components of the focal lymphocytic
inﬁltration in the salivary glands are CD4+ T lymphocytes. The evolution
of a malignant proliferation of B-lymphocytes from this inﬂammatory
inﬁltration is certainly a complex and multi-step process. The ultimate
step in this process is the transition from benign B cell proliferation to
malignant expansion. The uncontrolled expansion of B-lymphocytes is a
result of various genetic alterations, typically translocations involving
immunoglobulin gene loci and proto-oncogenes or other genes involved
in cell-cycle regulation. As an example of the several genetic transforma-
tions associated with lymphomagenesis in general, translocations
involving the MALT1 gene t(11;18)(q21;q21) and t(14;18)(q32;q21) are
considered as genetic events speciﬁc for MALT lymphoma. These
translocations have been found in only relatively small proportions of
26% and 15%, respectively, in SS MALT lymphoma patients [14]. Novel
mutations in the p53 tumour-suppressor gene have been detected in 2 of
5 SS low-grade lymphoma samples, and its pathogenetic signiﬁcance has
beenproposed [15]. However, consistentmolecular abnormalities relating
to lymphomagenesis in SS have not yet been conclusively identiﬁed. As
the possibility of an aberrant genetic event increases with the number of
cell divisions and with the intensity of the processes involving
immunoglobulin afﬁnity maturation and class switch recombination,
the role of SS-speciﬁc immunological processes and characteristics of the
local glandularmicroenvironment driving the perpetuated B-lymphocyte
proliferation need particular attention. The observation by Streubel et al.
that the classical t(11;18)(q21;q21) translocationwasdetected inonly1of
17 SS patients (6%)with extragastrointestinal lymphoma, as opposed to 6
of 9 SS patients (67%) with gastric MALT lymphoma further underlines
the role of potential pathogenetic factors in the salivary gland.
Labial salivary gland and parotid gland histological examinations
indicate awide spectrum in thedegree of lymphocytic inﬁltration ranging
from scattered perivascular lymphocytes to the diagnostic hallmark of
focal periductal lymphocytic inﬁltrates, containing B-lymphocytes,
macrophages and dendritic cells in addition to the predominant CD4+
T lymphocytes [12]. The increasing histologic score is not only aquantitative phenomenon; more intense inﬁltration is also associated
with increasing proportions of B-lymphocytes, a more pronounced
segregation of T and B cell compartments, and ﬁnally, the formation of
ectopic germinal centre-like structures resembling secondary follicles in
lymphoid organs, characterised by the presence of follicular dendritic cell
networks and high-endothelial venules. Several studies emphasize the
importance of ectopic germinal centre formation, concluding that this is a
sine qua non of NHL formation [12,13].
Malignant B cell clones arise as a result of an antigen-driven
process in these germinal centre-like structures. Analysis of these
clones from various patients has revealed a strikingly restricted
repertoire of immunoglobulin (Ig) heavy and light chain gene usage
[16]. The malignant marginal zone B-lymphocytes express hypermu-
tated, class-switched Ig-s indicating a positive selection from the B cell
repertoire probably involving T cell help [17]. Ig-s expressed by the
majority of the clonally expanding marginal zone B-lymphocytes have
rheumatoid factor properties, and it is feasible to hypothesise that
locally present Ig-s or (auto)antibody-containing immune-complexes
act as constant stimulators of the B cell receptors of these cells.
However, the antigen speciﬁcity of the malignant B-lymphocytes has
not been clariﬁed yet. It was also demonstrated that activation-
induced cytidin-deaminase (AID), the enzyme responsible for somatic
hypermutation in the Ig genes during the afﬁnitymaturation of B cells,
is expressed in SS salivary glands, notably exclusively in the germinal
centre-like structures [12]. This ﬁnding further supports the presence
of an antigen-driven clonal B cell proliferation in SS salivary glands.
A potential player in SS lymphomagenesis is presumably the
B-lymphocyte activator of the TNF-family (BAFF), a potent inducer and
perpetuating factor of B-lymphocyte activation and proliferation [18]. It
is highly up-regulated in several autoimmune diseases, with increased
mean serum levels in SS, even higher than in SLE or RA [19]. BAFF has
been found to be over-expressed in SS salivary glands, particularly by
glandular epithelial cells and inﬁltrating T lymphocytes [20]; serum
levels of BAFF have been shown to be correlated with the focus score of
the minor salivary gland inﬁltrates [21], and with germinal centre
formation [22]. Furthermore, BAFF-transgenic mice develop a SS-like
disease characterised by salivary gland focal lymphocytic inﬁltrations,
notably with a predominance of B-lymphocytes of the marginal zone B
cell phenotype [19]. BAFF has been shown to have a key role in
malignant B cell survival, moreover BAFF-production correlated with
the histological grade and patient survival in a study on NHL patients
[23]. Lymphocytes inﬁltrating the salivary gland have been found to
have an impaired ability to commit to apoptosis [24]. This defect seems
to be related to the increased expression of the anti-apoptotic mediator
of Bcl-2. Interestingly, one mechanism whereby BAFF leads to excess B
cell survival is the induction of Bcl-2 [23]. Furthermore, BAFF has also
been implicated in lymphoma development in chronic hepatitis C virus
infection, a process showing many similarities with the lymphomagen-
esis in SS, including the strong predictive potential of mixed cryoglo-
bulinaemia [25–28]. Finally, BAFFwas demonstrated to up-regulate AID,
and promote class switch recombination in human B-lymphocytes via
the activation of p38 MAPK [29]. Taken together, these observations
strongly suggest that BAFF is a realistic candidate contributor to
lymphomagenesis in SS with potential therapeutic implications either
as a target, or as a prognostic factor. In this context, Quartuccio et al. have
presented a case with SS and lymphoma, where serum BAFF levels
appeared to correlate with the therapeutic response to rituximab and
prednisolone [30–32]. However, further evidences with regard to BAFF
and lymphoma evolution in SS are required.
An interesting observation sheds light on further potential cytokine
interactions at the site of active B cell proliferation. Asmentioned above,
BAFF-transgenic mice have a strong tendency to develop lymphocytic
sialadenitis reminiscent of SS [19]. BAFF-transgenicmice lacking tumour
necrosis factor-α (TNF-α)—while developing a disease similar to TNF-α
producing mice—demonstrated a strikingly increased susceptibility to
MALT lymphoma development [33]. On the other hand, BAFF has been
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extensive local production of IL-10 has been speculated to be associated
with B-lymphocyte hyperactivity and lymphoma development [35,36]
although formal proofs havenot beenpresented. Adetailed examination
of the Th1/Th2 balance in lymphocytes inﬁltrating the salivary glands
concluded that this cytokine balance may change with time during the
evolution of SS [37]. Although the precise role of the particular cytokines
in SS has not been fully understood, emerging data suggest a signiﬁcant
contribution of the local cytokine milieu to lymphoma development,
and these observationsmay lead to therapeutically relevant conclusions.
A striking redistribution of B-lymphocytes in SS patients has been
described by Hansen et al. [38]. In this study, a signiﬁcant reduction of
CD27+ memory B cells was found in the circulation, in contrast with
increased numbers in the parotid gland; moreover, memory B-
lymphocytes in the salivary gland exhibited a higher Ig VH gene
mutational frequency. This ﬁnding is in contrast with data from patients
with SLE, where increased numbers of CD27+ memory B cells and
CD27high plasma cells are associatedwith increased disease activity [39].
Theﬁndings inSS are consistentwith anaccumulationofmemoryB cells
in the target glands. In this context, an abundant expression of two
chemokines, CXCL13 and CCL21 was observed in SS salivary glands;
these two B cell attracting chemokines are considered crucial in the
formation of lymphoid tissue, including ectopic germinal centres [40].
Notably, CXCL13 andCCL21 expressionwas foundonly in areas of benign
lymphoepithelial lesions, and was abandoned in tissue sections with
lymphomatous proliferation. On the other hand, the chemokine CXCL12
was found to be selectively up-regulated in areas of malignant
lymphocytic inﬁltrations, mostly by ductal epithelial cells and—in an
autocrine way—bymalignant B cells. These ﬁndings raise the possibility
that increased production of B cell attracting chemokines by resident
and inﬁltrating cells may contribute to the accumulation and subse-
quent constant stimulation of memory B-lymphocytes. The shift in the
chemokine proﬁle in the involved tissue may form a basis for the
selective glandular retention ofmalignant B cells, thereby increasing the
chance of a sustained malignant proliferation.
5. Summary
The evolution of lymphoma in SS is a result of a multi-step process
that starts as focal mixed cellular inﬁltrations of the involved glands,
most importantly the salivary glands, gradually leading to tissue injury
and the appearance of symptoms of exocrine insufﬁciency. In many SS
cases this glandular cellular inﬁltration progresses through the
compartmentalisation of the lymphoid cellular elements to ectopic
germinal centre formationand increasingpolyclonal B cell hyperactivity.
These patients often have high levels of serum IgG, andmost of themare
anti-Ro/SSA and/or-La/SSB, aswell as rheumatoid factor positive. Due to
further, poorly understood steps, probably driven by changes in the local
chemokine and cytokine milieu and genetic aberrations, monoclonal B
cell lines arise that generally produce monoclonal immunoglobulins of
rheumatoid factor activity and cryoprotein characteristics. The type II or,
less often, type III cryoglobulinaemia leads to the typical immune-
complex-mediated symptoms of vasculitis, inﬂammatory neuropathy,
immune-cytopenia and, occasionally, immune-complex mediated glo-
merulonephritis. These patients typically have low C4 levels, are
cryoglobuline-positive, and occasionally monoclonal paraproteins can
be detected in the serum or monoclonal light chains in the urine. The
increasing lymphoproliferation causes parotidomegaly or lymphadeno-
pathy. Further alterations in these highly proliferative monoclonal B-
lymphocyte clones, probably involving the dysfunction of cell-cycle
regulation, eventually lead to malignant proliferation, and the clinical
picture of an NHL. The better understanding of this clinico-pathologic
scenario may help clinicians to identify SS patients, who are at an
increased risk of NHL development.
The careful follow-up and regular assessment of serum immuno-
electrophoresis, cryoglobuline assay, urinary free light chain assay andthorough physical and instrumental examinations of the relevant
exocrine glands, lymphatic glands and all the locations of a potential
lymphoma aid to identify SS patients with NHL in an early stage and
give ground to initiate therapeutic interventions prior to the propaga-
tion of the disease.
Take-home messages
• Non-Hodgkin's B cell lymphoma develops in 5% of SS patients.
• Parotidomegaly, neuropathy, vasculitis, lymphadenopathy, cryoglo-
bulinaemia and monoclonal paraproteinaemia are predictive of
lymphoma development.
• Lymphoma usually arises at extranodal sites as a result of ectopic
lymphoid tissue formation and antigen-driven hyperproliferation of
rheumatoid factor-secreting B cells.
• B-lymphocyte activating factor is presumably an important factor in
the stimulation of B-lymphocyte proliferation.
• Over-expression of B-lymphocyte attracting chemokines may con-
tribute to the glandular retention of malignant B cells.
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